Researchers at the American Association for Cancer Research recently published an article, “Immune Checkpoint Blockade Enhances Shared Neoantigen-Induced T Cell Immunity Directed against Mutated Calreticulin in Myeloproliferative Neoplasms,” highlighting the restoration of T-cells specific to fighting the CALR mutation in MPN patients. Utilization of checkpoint blockades confirmed mut-CALR as an effective immunogen that can be used as an MPN-specific neoantigen. Current MPN treatments do not effectively target these malignant CALR cells, but these findings are potentially promising for the future of MPN immunotherapy.
PROMISING RESULTS OF NEW AACR STUDY
MPNRF | April 6, 2021